We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

168 hedge funds and large institutions have $1.36B invested in Pacira BioSciences in 2018 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 58 increasing their positions, 60 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

4.17% more ownership

Funds ownership: 103.26% → 107.43% (+4.2%)

3% less repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 60

9% less funds holding

Funds holding: 185 → 168 (-17)

29% less capital invested

Capital invested by funds: $1.91B → $1.36B (-$550M)

36% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 42

57% less call options, than puts

Call options by funds: $12M | Put options by funds: $27.9M

60% less funds holding in top 10

Funds holding in top 10: 5 → 2 (-3)

Holders
168
Holders Change
-17
Holders Change %
-9.19%
% of All Funds
3.85%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.05%
New
27
Increased
58
Reduced
60
Closed
42
Calls
$12M
Puts
$27.9M
Net Calls
-$15.9M
Net Calls Change
-$27.9M

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$60.7M
2
CCM
Consonance Capital Management
New York
+$36.8M
3
ACA
Avoro Capital Advisors
New York
+$30.9M
4
PC
PointState Capital
New York
+$30.2M
5
Jennison Associates
Jennison Associates
New York
+$18.3M

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$23.3M
2
VOYA Investment Management
VOYA Investment Management
Georgia
-$20.3M
3
HM
HealthCor Management
New York
-$17.8M
4
Invesco
Invesco
Georgia
-$17.5M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$17.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
51
Invesco
Georgia
$5.01M -$17.5M -490,792 -75%
MOACM
52
Mutual of America Capital Management
New York
$4.2M -$638K -17,909 -12%
Morgan Stanley
53
Morgan Stanley
New York
$4.11M +$375K +10,525 +9%
TA
54
Tamarack Advisers
California
$3.7M -$6.99M -196,298 -62%
USAA
55
United Services Automobile Association
Texas
$3.59M +$57.8K +1,622 +1%
PAMU
56
Pictet Asset Management (UK)
United Kingdom
$3M +$2.3M +64,552 +204%
LCM
57
Laurion Capital Management
New York
$2.99M +$3.42M +96,126 New
AQR Capital Management
58
AQR Capital Management
Connecticut
$2.8M +$3.2M +89,828 New
Skandinaviska Enskilda Banken (SEB)
59
Skandinaviska Enskilda Banken (SEB)
Sweden
$2.6M +$2.58M +72,500 +671%
ECM
60
Element Capital Management
New York
$2.41M -$2.04M -57,175 -42%
PPA
61
Parametric Portfolio Associates
Washington
$2.27M -$210K -5,893 -7%
TA
62
Teachers Advisors
New York
$2.24M – – –
Swiss National Bank
63
Swiss National Bank
Switzerland
$2.17M – – –
MWNA
64
Marshall Wace North America
New York
$2.16M -$81.2K -2,280 -3%
GC
65
Guggenheim Capital
Illinois
$2.14M +$431K +12,112 +21%
California Public Employees Retirement System
66
California Public Employees Retirement System
California
$2.02M -$110K -3,100 -5%
Hudson Bay Capital Management
67
Hudson Bay Capital Management
Connecticut
$1.9M +$2.17M +61,000 New
California State Teachers Retirement System (CalSTRS)
68
California State Teachers Retirement System (CalSTRS)
California
$1.89M -$49.4K -1,388 -2%
AllianceBernstein
69
AllianceBernstein
Tennessee
$1.83M +$14.9K +418 +0.7%
SSA
70
Schonfeld Strategic Advisors
New York
$1.74M +$1.98M +55,731 New
AA
71
ALPS Advisors
Colorado
$1.7M +$337K +9,457 +21%
Ohio Public Employees Retirement System (OPERS)
72
Ohio Public Employees Retirement System (OPERS)
Ohio
$1.6M +$148K +4,159 +9%
HCM
73
Highbridge Capital Management
New York
$1.56M -$3.56M -100,000 -67%
LCP
74
Legacy Capital Partners
Wisconsin
$1.54M -$39.3K -1,105 -2%
Russell Investments Group
75
Russell Investments Group
United Kingdom
$1.54M +$678K +19,031 +63%
1 2
3
4 5

PCRX Hedge Fund Activity: Q1 2018 in Review

168 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q1 2018, worth a combined $1.36B — down 29% from $1.91B a quarter earlier.

Sellers outnumbered buyers: 42 funds closed out of PCRX and 27 opened new positions — a net loss of 15 holders — while 60 trimmed existing stakes and 58 added.

The largest buyer was PFM Health Sciences, opening a new position worth an estimated $60.7M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $23.3M sold.

  • 168 institutional investors held Pacira BioSciences (PCRX) as of Q1 2018, down from 185 in Q4 2017.
  • Funds reported $1.36B of Pacira BioSciences stock for Q1 2018, down 29% quarter-over-quarter.
  • 27 funds opened new Pacira BioSciences positions in Q1 2018 and 42 closed out, a net change of -15 holders.
  • The largest Pacira BioSciences buyer in Q1 2018 was PFM Health Sciences, an estimated $60.7M added.
  • The largest Pacira BioSciences seller in Q1 2018 was Renaissance Technologies, an estimated $23.3M sold.

Based on aggregated 13F filings for Q1 2018.